Steve Gaudin, MD
Family Medicine · Ponchatoula, LANPI 1649269390
Payments from drug & device makers
Across 380 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- Pfizer$571
- AbbVie$537
- Sunovion Pharmaceuticals Inc.$447
- Amgen$253
- Amarin Pharma, Inc.$191
- plus $1K from 24 others
What the payments were for
- Food & beverage$5,832100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 164 | $2,631 |
| Pfizer | 38 | $571 |
| AbbVie(2 entities) | 49 | $537 |
| Sunovion Pharmaceuticals Inc. | 29 | $447 |
| Amgen | 14 | $253 |
| Amarin Pharma, Inc. | 11 | $191 |
| E.r. Squibb & Sons, L.L.C. | 9 | $150 |
| Novo Nordisk | 10 | $147 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $134 |
| Boston Scientific | 2 | $110 |
| Novartis | 6 | $107 |
| Johnson & Johnson | 5 | $79 |
| Merck | 3 | $61 |
| Esperion Therapeutics, Inc. | 4 | $54 |
| Abbott | 2 | $42 |
| Lilly USA, LLC | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Clarus Therapeutics Inc. | 2 | $29 |
| Antares Pharma, Inc. | 1 | $27 |
| Boehringer Ingelheim | 2 | $27 |
| AstraZeneca | 2 | $25 |
| Ardelyx, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Sumitomo Pharma America, Inc. | 5 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Radius Health, Inc. | 1 | $14 |
| OPKO Pharmaceuticals, LLC | 1 | $14 |
| Sanofi | 1 | $11 |
How this compares
$5,832 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 303 | $166,002 |
| MounjaroTirzepatide | 93 | $105,775 |
| JanuviaSitagliptin Phosphate | 139 | $97,068 |
| XifaxanRifaximin | 57 | $92,248 |
| OzempicSemaglutide | 65 | $65,678 |
| LinzessLinaclotide | 102 | $57,341 |
| JardianceEmpagliflozin | 85 | $50,052 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $46,878 |
| TrulicityDulaglutide | 42 | $44,342 |
| XareltoRivaroxaban | 51 | $41,851 |
| TradjentaLinagliptin | 68 | $28,277 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $20,661 |
| Spiriva HandihalerTiotropium Bromide | 29 | $16,191 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $15,382 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $15,351 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $571 | $166,002303 claims |
| Lilly USA, LLCMounjaro, Trulicity | $35 | $150,117135 claims |
| MerckJanuvia, Janumet, Dulera | $61 | $108,114175 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $134 | $92,24857 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $27 | $90,961164 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $2,631 | $82,889132 claims |
| Novo NordiskOzempic, Rybelsus | $147 | $77,39676 claims |
| AbbVieLinzess | $537 | $57,341102 claims |
| Johnson & JohnsonXarelto | $79 | $41,85151 claims |
| NovartisEntresto | $107 | $12,95633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Ponchatoula
- Gregory AllenPonchatoula$23K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.